35 episodes

The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.

The BioInsights Podcast BioInsights

    • Science
    • 5.0 • 2 Ratings

The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.

    Can AAV continue to deliver the promise of gene therapy?

    Can AAV continue to deliver the promise of gene therapy?

    In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senior Strategy Consultant at Merck Life Sciences. 

    • 21 min
    Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

    Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

    The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field.  In this episode, David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.

    • 20 min
    Investing long-term in the cell & gene therapies of the future

    Investing long-term in the cell & gene therapies of the future

    David McCall, Senior Editor, BioInsights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital, about her VC company's portfolio of advanced therapy investments, and the keys to obtaining funding in a difficult environment. (From an interview conducted on February 22nd, 2023).

    • 15 min
    Happy medium: considerations in scaling cell culture media strategies

    Happy medium: considerations in scaling cell culture media strategies

    While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast,  Charlotte Barker, Editor, BioInsights, speaks to Dalip Sethi, Director of Scientific Affairs, Terumo BCT, about best practices for scaling up cell culture substrate.

    • 19 min
    Applying multiomics to novel target discovery in immuno-oncology

    Applying multiomics to novel target discovery in immuno-oncology

    In this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about the advantages of using multiomic and computational approaches for the discovery of novel targets and mechanisms of action (MoA) of novel drug candidates in immuno-oncology.

    • 18 min
    Modernizing cell therapy manufacturing to reduce vein-to-vein times

    Modernizing cell therapy manufacturing to reduce vein-to-vein times

    Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.

    • 23 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Science

Hidden Brain, Shankar Vedantam
WNYC Studios
Alie Ward
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Sam Harris
Neil deGrasse Tyson

You Might Also Like

Erin Harris
Matt Pillar
BioCentury
Hidden Brain, Shankar Vedantam